Its hard to top Humira :-)... With some thought I may be able to think of some that were more meaningful to the company on a percentage of its future growth but no where near the dollar amount of Humira.
I guess for all the hype Vertex has made about their science being better its interesting their biggest market cap gain is coming from something not discovered inhouse.
For what its worth I am in the camp that their CF drugs could justify the market cap (and then some) if they are affecting the underlying disease as some headlines have said. I don't know enough about the drugs to know if that is really the case or not. I just look at ERT drugs and some of those results weren't overly impressive in short trials but they are really life saving. I've been a big critic of VRTX in the past too (though in the 30 range I got tempted but seeing new management sound like Boger discouraged me).
Market Data 
Markets 
AI
